Pharmaceutical company Ipsen is set to purchase French biotechnology company ImCheck Therapeutics to develop acute myeloid leukaemia (AML) treatment ICT01. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, which received Orphan Drug Designations from the US Food and Drug Administration and European Medicines Agency in July 2025. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!